Skip to content
OpenCapital
Get started

Jazz Pharmaceuticals JAZZ Equity Securities Without Readily Determinable Fair Value - Cumulative Downward Adjustments

Equity Securities Without Readily Determinable Fair Value - Cumulative Downward Adjustments at other companies

ResMed logo
ResMedRMD
——

Other financials

Income statement

See full
Revenue$1.1B+19.1%
Operating income$336.6M+702%
Net income$293.1M+417%
EPS (diluted)$4.43+391%

Balance sheet

See full
Cash & equivalents$667.5M-64.1%
Total debt$5.4B-0.1%
Total equity$4.5B+8.6%
Total assets$11.9B+2.8%

Cash flow

See full
Operating cash flow$408.2M-5.0%
CapEx$19.7M+41.7%
Free cash flow$388.5M-6.6%

Valuation

See full
Market cap$14.11B+54.4%
Enterprise value$18.85B+47.7%
P/S3.2×+0.9×

Profitability

See full
Operating margin-11.9%-28.1pp
Net margin-8.9%-20.5pp
FCF margin28.6%-8.6pp

Returns & leverage

See full
Return on equity-9.1%-21.2pp
Debt / equity1.2×-0.1×
Current ratio2×-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount.

The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Jazz Pharmaceuticals's equity securities without readily determinable fair value - cumulative downward adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Jazz Pharmaceuticals's equity securities without readily determinable fair value - cumulative downward adjustments?
Jazz Pharmaceuticals (JAZZ) reported equity securities without readily determinable fair value - cumulative downward adjustments of $4.3M in Q1 2026.
How has Jazz Pharmaceuticals's equity securities without readily determinable fair value - cumulative downward adjustments changed year-over-year?
Jazz Pharmaceuticals's equity securities without readily determinable fair value - cumulative downward adjustments decreased by 0.0% year-over-year, from $4.3M to $4.3M.
What is the long-term trend for Jazz Pharmaceuticals's equity securities without readily determinable fair value - cumulative downward adjustments?
Over 3 years (2022 to 2025), Jazz Pharmaceuticals's equity securities without readily determinable fair value - cumulative downward adjustments has grown at a -7.9% compound annual growth rate (CAGR), from $5.5M to $4.3M.